Prolactin receptor status as a risk factor for progression from gestational diabetes to type 2 diabetes
Summary
This study will determine whether presence of a specific gene may increase the risk of developing diabetes in women who were first found to have diabetes during their pregnancy.
Diabetes first identified during pregnancy, more commonly referred to as gestational diabetes (GDM), is relatively common, affecting up to 20% of pregnancies. It is associated with an increased risk of both maternal and neonatal complications. Importantly, GDM is a major risk factor for the postpartum development of pre-diabetes or type 2 diabetes (T2D). Specifically, half of women with gestational diabetes will develop pre-diabetes or T2D within 10 years of delivery. Currently, we don’t have a clear understanding of why some women with a history of GDM progress to T2D shortly postpartum while some may take years to progress to T2D. A clear understanding of the risk factors for the GDM-to-T2D progression will help us identify high risk individuals and allow us to find a strategy to delay and prevent this progression.
This study will test whether the presence of a specific gene, which has no known health effect in human so far, is a risk factor for GDM-to-T2D progression.
Eligibility
Eligible gender: Transgender, Female
Eligible ages: 18 to 45
Accepts healthy participants: Yes
Inclusion criteria:
Participants of the PREDISPOSE study.
For the PREDISPOSE study, the inclusion criteria are:
1. Pregnant individuals age ≥ 18 years at time of recruitment
2. A diagnosis of gestational diabetes by the Diabetes Canada Clinical Practice Guidelines (including both the preferred or alternate testing approaches)
• Have any of the following:
o Have an elevated fasting glucose (≥5.3 mmol/L) on the diagnostic 75g OGTT in pregnancy
o Required insulin or metformin for treatment during pregnancy
o Body mass index (BMI) ≥ 25 kg/m2, yes/no (<27 weeks gestation BMI of ≥25 kg/m2 or ≥27 weeks gestation predicted BMI of ≥ 25 kg/m2 using (current weight in kg – 10kg)/height in meters2)
• Planned in-hospital delivery
• Able to provide informed consent
• Have access to email
The Exclusion criteria are:
1. Non-gestational diabetes (i.e. pre-existing diabetes)
2. On medications known to affect glucose metabolism (for example glucocorticoids, metformin etc.)
3. Unable to speak and understand French or English
4. Unable to consent or declined informed consent
Exclusion criteria:
All women who were diagnosed with diabetes before becoming pregnant.
Participate
Additional information
Contact information
Heidi Virtanen 587-943-2751
Principal investigator:
Carol Huang
Clinical trial:
No
REB-ID:
REB23-0170